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eNOS G894T polymorphism as a mild
predisposing factor for abdominal aortic aneurysm
Cinzia Fatini, MD, PhD,a Francesco Sofi, MD,a Elena Sticchi, BS,a Paola Bolli, BS,a Ilaria Sestini, BS,a
Michela Falciani, MD,a Leonidas Azas, MD,b and Giovanni Pratesi, MD,b Florence, Italy
Objective: Abdominal aortic aneurysm (AAA) represents a chronic degenerative condition associated with atherosclerosis.
Actually, data from experimental and clinical studies suggest that nitric oxide (NO) is a modulator in maintaining
endothelial function and antithrombotic intravascular environment. Reduced vascular NO generation in subjects
carrying the rare variants of the eNOS gene might predispose to AAA. No information is available about the influence of
the eNOS gene T-786C, G894T, and 4a/4b polymorphisms in the susceptibility to the disease.
Methods: In this study, we evaluated the role of these polymorphisms in the predisposition to AAA and their influence in
hypertensive and normotensive patients. We studied 250 consecutive patients with AAA referred to the Unit of Vascular
Surgery of the University of Florence compared with 250 truly healthy subjects with a negative history of vascular
diseases. All subjects, patients, and controls, underwent duplex scanning examination, and to assess the presence of other
atherosclerotic localizations, all patients underwent clinical and instrumental examinations.
Results: A significant difference in genotype distribution and allele frequency was observed for eNOS G894T but not for
T-786C and 4a/4b polymorphisms. At the multivariate analysis after adjustment for traditional vascular risk factors and
other atherosclerotic localizations, the eNOS 894T variant was significantly associated with AAA, according to dominant
and recessive models (dominant model odds ratio [OR]: 2.2, 95% confidence interval [CI]: 1.21-3.93, P .007; recessive
model OR: 2.7, 95% CI: 1.42-5.20, P .002). When patients with other atherosclerotic localizations were excluded from
the analysis, the 894T variant still remained associated with the predisposition to AAA, according to the models
considered (dominant model OR: 2.1, 95%CI: 1.23-3.92, P  .007; recessive model OR: 2.8, 95%CI: 1.45-5.24, P 
.002).
Conclusions: The present study showed that the eNOSG894T polymorphism is a mild modulator of the predisposition to
AAA apart from traditional risk factors, suggesting a genetic influence on the molecular mechanisms responsible for this
complex disease. ( J Vasc Surg 2005;42:415-9.)Abdominal aortic aneurysm (AAA), which is a chronic
degenerative condition, is associated with atherosclerosis.
Actually, data from experimental1 and clinical2 studies sug-
gest that nitric oxide (NO) is a modulator of vascular
disease and its physiologic effects are addressed to maintain
endothelial function and antithrombotic intravascular en-
vironment; NO contributes to vascular tone regulation,
inhibition of platelet aggregation,3 and leukocyte adhesion
to vascular endothelium4 and inhibits smooth muscle cell
migration and proliferation.5 All these actions likely pre-
vent the development of atherosclerotic plaque. Moreover,
experimental data from endothelial NO synthase (eNOS)
knockout mice model demonstrated that, in the absence of
eNOS, the luminal remodeling is impaired and the vessel
wall thickness is doubled, suggesting that endothelium-
derived NO, in addition to its role as a vasodilator, may
have a role in controlling vessel wall geometry.6
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doi:10.1016/j.jvs.2005.05.044The multifactorial pathogenesis of AAA includes envi-
ronmental and genetic factors interacting to produce the
AAA phenotype. Gene encoding for eNOS has been pro-
posed as a candidate gene for AAA3 and polymorphic
variants in this gene influence the expression and functional
activity of the enzyme. In exon 7 of the eNOS gene, the
G894T polymorphism has been associated with reduced
basal NO production.7 The mechanism by which eNOS
G894T polymorphismmight reduce NObioavailability has
been related to a selective proteolytic cleavage in endothe-
lial cells and vascular tissues. Since these cleaved fragments
would be expected to lack NOS activity, this could account
for reduced vascular NO generation in subjects carrying the
rare variant.8
Another polymorphism in the promoter region of the
same gene, called T-786C, is responsible for a reduction of
more than 50% in the eNOS gene promoter activity, as
assessed by luciferase reporter gene assay. The -786C rare
allele has been described to be associated with a reduced
NO production.9 Finally, in intron 4, a variable nucleotide
tandem repeat (VNTR) has been identified. This polymor-
phism, also called 4a/4b, has been associated with altered
plasma NO levels10 and has been found to be responsible
for variations in the genetic control of plasma nitrite and
nitrate levels.11 Since this polymorphism is intronic, it has
been proposed that it might act as a marker in linkage
disequilibrium with other functional variants in regulatory
regions of the gene.12
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eNOS 4a/4b polymorphism on the clinical course of AAA
progression,3 but no data are available on the role of all
three eNOS polymorphisms in the predisposition to AAA.
In the present study we evaluated (1) the role of eNOS
T-786C, G894T, and 4a/4b polymorphisms in the predis-
position to AAA and (2) their influence in hypertensive and
normotensive patients.
METHODS
Study population
We enrolled 270 consecutive patients with AAA re-
ferred to the Unit of Vascular Surgery of the University of
Florence. AAAwas defined as a focal dilation of the abdom-
inal aorta at least 50% larger than the expected normal
diameter, according to the current report standard.13 Fa-
milial (n  13) and inflammatory (n  7) AAAs were
excluded from the study. Indeed, familial AAA was consid-
ered in patients with one or more first-degree family mem-
bers with AAAmentioned by the patient and/or diagnosed
by a physician, whereas inflammatory AAA was diagnosed
on the basis of operative appearance (presence of extensive
perianeurysmal and retroperitoneal fibrosis and dense ad-
hesions to adjacent abdominal organs). The final study
population comprised 250 AAA patients. A group of 250
truly healthy subjects matched for age and gender were
recruited from partners or friends of patients and were used
as controls. All controls had a negative history of vascular
diseases, as evaluated by expert physicians in the physical
examination. Patients and controls were whites from cen-
tral and southern Italy. All subjects gave informed consent,
and the study was approved by the local ethics committee.
All subjects, patients and controls, underwent duplex scan-
ning examination using an Acuson Sequoia Color Duplex
System (Mountain View, Calif) with a multifrequency con-
vex probe, ranging from 5 to 2MHz. Ultrasound scanning
examination was then confirmed in patients by angiogra-
phy/computed tomography scan. Digital subtraction an-
giography was performed only in patients with concomi-
tant peripheral arterial disease and in candidate patients for
endovascular treatment of AAA when angiography/com-
puted tomography study was not satisfactory to evaluate
the feasibility of endovascular treatment. Aortic diameter
was measured below the origin of renal arteries in both
groups. The subjects were considered to have hypertension
if they had been diagnosed according to the guidelines of
European Society of Hypertension/European Society of
Cardiology14 or were taking antihypertensive drugs. Dys-
lipidemia was defined according to the Third Report of the
National Cholesterol Education Program.15
To assess the presence of other atherosclerotic localiza-
tions, all patients underwent clinical and instrumental ex-
aminations (electrocardiography, echocardiography, and
duplex scanning with color-coded echo flow imaging on
carotid arteries and ankle/brachial pressure index evalua-
tion). In patients with symptoms possibly related to isch-
emic heart disease, further investigations were performed(echocardiography on drug-induced stress testing, myocar-
dial scintigraphy, and coronary angiography). Severe ca-
rotid stenosis, confirmed by angiography/computed to-
mography, was defined according to the North American
Symptomatic Carotid Evaluation Trial criteria.16 Peripheral
arterial disease was documented as present if ankle/brachial
pressure index was less than 0.9. On the basis of these
criteria, 71 (28%) patients had clinical evidence of coronary
artery disease (CAD), 25 patients (10%) had cerebrovascu-
lar disease (CVD), and 49 (19%) peripheral arterial disease
(PAD).
Aneurysm size was measured by means of computed
tomography both in patients and in controls.
Genetic analysis. eNOS polymorphisms were ana-
lyzed after genomic DNA extraction from peripheral blood
leukocytes using a QIAmp Blood Kit (QIAGEN, Hilden,
Germany).
eNOS T-786C polymorphism. The eNOS T-786C
polymorphism has been analyzed by polymerase chain re-
action–restriction fragment length polymorphism (PCR-
RFLP) analysis. PCR reaction was performed using prim-
ers: 5=-GTGTACCCCACCTGCATTCT-3= (sense) and
5=-CCCAGCAAGGATGTAGTGAC-3= (anti-sense), and
DNA (100 ng) was amplified in a final volume of 20 L at
an annealing temperature of 60°C using a DNA thermal
cycler. The PCR detection was followed by Turbo Nae
restriction endonuclease digestion for 4 hours at 37°C and
resolution by electrophoresis on 2% agarose gel.
eNOS 4a4b polymorphism. The eNOS 4a4b poly-
morphism has been analyzed by PCR-amplification. PCR
reaction was performed using primers: 5=-CTATGG-
TAGTGCCTTGGCTGGAGG-3= (sense) and 5=-AC-
CGCCCAGGGAACTCCGCT-3= (anti-sense) and DNA
was amplified in a final volume of 20 L at an annealing
temperature of 58°C. The amplified products were ana-
lyzed by electrophoresis on a 3.5% agarose gel.
eNOS G894T polymorphism. The eNOS G894T
polymorphism detection was performed by real-time fluo-
rescence PCR using the Light Cycler instrument (Roche
Diagnostics).
PCR and melting curve determination were performed
in a final volume of 20 L with 10 pmol of each primer
NOSF (5=-CACTCCCCACAGCTCTGCAT-3=) andNOSR
(5=-CAATCCCTTTGGTGCTCACG-3=), and 4 pmol of
each probe (anchor probe and sensor probe). The anchor
probe (5=-LC Red 640-CCTTCTGCCCCCCGAGCTG-
GTCC-3=-P) was 5= labeled with the LC-Red 640 fluoro-
phore and phosphorylated (P) at its 3= end to prevent probe
elongation by the Taq polymerase. The sensor probe (5=-
CCCCAGATGATCCCCCAGAACTC-3= FLU)was labeled
with fluorescein. DNA was amplified at an annealing temper-
ature of 62°C.
The typical melting curve pattern is a single melting
peak at a temperature of 65.5°C. For the wild type, the plot
is a single melting peak at a temperature of 60.5°C. Het-
erozygous patients show two melting peaks (60.5°C and
65.5°C).17
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Statistical analysis was performed by using the Statisti-
cal Package of Social Sciences (SPSS, Chicago, Ill) software
for Windows (Version 11.5). Data are expressed as median
and range. Aortic diameter was expressed as mean  SD.
The 2 test was used to test for proportions and deviations
of genotype distribution from Hardy-Weinberg equilib-
rium. eNOS T-786C, G894T, and 4a/4b allele frequencies
were obtained by direct count. The number of subjects
studied was sufficient to detect, with a statistical power of
80% (  0.8) and significance value of .05 (), absolute
difference for eNOS G894T polymorphism. The nonpara-
metric Mann-Whitney test was used for comparisons be-
tween single groups. Kruskal-Wallis test was used for com-
parisons among different groups. To assess different models
at each locus, genotypes at each position were coded as
recessive model (eg, eNOS-786CC vs -786TCTT) and as
dominant model (eg, eNOS-786CCTC vs TT). The rela-
tionship between the three polymorphisms and AAA was
determinedbyunivariate logistic regression analysis. Variables
showing, at univariate analysis, a statistically significant
association with AAA were introduced in a multivariate
model to evaluate the association with the disease after
adjustment for traditional cardiovascular risk factors. Odds
ratio (OR) with 95% confidence interval (CI) was deter-
mined. P .05 was considered to indicate statistical signif-
icance.
RESULTS
Demographic and clinical characteristics of the study
population are described in Table I. We observed signifi-
cant differences between the two groups for traditional
cardiovascular risk factors. Genotype distribution and allele
frequency of eNOS T-786C, G894T, and 4a/4b polymor-
phisms were in Hardy-Weinberg equilibrium and are re-
ported in Table II.
A significant difference in both genotype distribution
and allele frequency between patients and healthy subjects
was observed for eNOS G894T, but not for eNOS T-786C
Table I. Demographic characteristics and traditional risk
factors for cardiovascular diseases
Variable
Patients
(n  250)
Healthy
subjects
(n  250) P
Age (y) 72 (50-83) 71 (49-87) .06
Males, no. (%) 217 (86.8) 216 (86.4) .9
Females, no. (%) 33 (13.2) 34 (13.6) .8
Hypertension, no. (%) 185 (74) 48 (19.2) .0001
Dyslipidemia, no. (%) 107 (42.8) 36 (14.4) .0001
Smoking habit, no. (%) 180 (72) 62 (24.8) .0001
Diabetes, no. (%) 12 (4.8) 9 (3.6) .5
Abdominal aortic
diameter (cm)
6.5  1.3 1.7  1.1 .0001
Median and (range) for age; mean  SD for abdominal aortic diameter.and 4a/4b polymorphisms.The univariate logistic regression analysis showed a
significant association of eNOS 894T, but not of -786C and
4a alleles and AAA according to dominant and recessive
models (eNOS 894T dominant model OR: 1.94, 95% CI:
1.3	2.8, P  .0001 and recessive model OR: 2.91, 95%
CI: 1.8	4.7, P  .0001) (Table III). After adjustment for
age, gender, smoking habit, hypertension, dyslipidemia,
and other atherosclerotic localizations (Table III), the
eNOS 894T variant was found to be significantly associated
with AAA, according to the models considered. The con-
Table II. Genotype distribution and allele frequencies of
eNOS T-786C, G894T, and 4a4b polymorphisms
Genotype Allele
Patients
(n  250)
No. (%)
Healthy
subjects
(n  250)
No. (%) P
eNOS -786 CC 46 (18.4) 42 (16.8)
eNOS -786 TC 115 (46.0) 116 (46.4)
eNOS -786 TT 89 (35.6) 92 (36.8) .9*
-786C 0.41 0.40 .6†
eNOS 894 TT 69 (27.6) 29 (11.6)
eNOS 894 GT 109 (43.6) 110 (44.0)
eNOS 894 GG 72 (28.8) 111 (44.4) .0001*
894T 0.49 0.34 .0001†
eNOS 4a4a 8 (3.2) 7 (2.8)
eNOS 4a4b 73 (29.2) 68 (27.2)
eNOS 4b4b 169 (67.6) 175 (70.0) .8*
4a 0.18 0.16 .5†
*Genotype distribution.
†Allele frequency.
Table III. Odds ratios associated with eNOS
polymorphisms for AAA according to different models:
univariate and multivariate analyses
OR 95% CI P
Univariate analysis
Age 1.02 0.9-1.05 .08
Gender (males vs females) 1.4 0.7-3.04 .4
Hypertension 11.3 7.4-17.1 .0001
Smoking habit 7.8 5.2-11.6 .0001
Dyslipidemia 4.5 2.9-6.9 .0001
Diabetes 0.7 0.3-1.8 .5
eNOS 894T (dominant model) 1.9 1.3-2.8 .0001
eNOS 894T (recessive model) 2.9 1.8-4.7 .0001
eNOS -786C (dominant
model)
1.05 0.7-1.5 .8
eNOS -786C (recessive model) 1.1 0.7-1.8 .6
eNOS 4a (dominant model) 1.1 1.7-1.6 .6
eNOS 4a (recessive model) 1.2 0.4-3.2 .8
Multivariate analysis*
Smoking habit 8.6 4.9-15.1 .0001
Hypertension 10.4 5.9-18.4 .0001
Dyslipidemia 2.5 1.3-4.7 .007
eNOS 894T (dominant model) 2.2 1.2-3.9 .007
eNOS 894T (recessive model) 2.7 1.4-5.2 .002
OR, Odds ratio; AAA, abdominal aortic aneurysm; CI, confidence interval.
*Adjusted for age, gender, traditional vascular risk factor, and other athero-
sclerotic localizations.comitant presence of eNOS 894T rare allele and the other
JOURNAL OF VASCULAR SURGERY
September 2005418 Fatini et altwo rare variants (-786C and 4a) did not affect the predis-
position to AAA (eNOS 894T and -786C vs 894G and
-786T OR: 1.39, 95% CI: 0.5	3.8, P  .5; eNOS 894T
and 4a vs. 894G and 4b OR: 0.65, 95% CI: 0.01	0.9, P
.9). When patients with other atherosclerotic localizations
(ie, CAD, PAD, and CVD) were excluded from the analy-
sis, the eNOS 894T allele still remained significantly asso-
ciated with a predisposition to AAA, according to the
models considered (eNOS 894T dominant model OR: 2.2,
95% CI: 1.2	3.9, P .007 and OR 894T recessive model
OR: 2.8, 95% CI: 1.4	5.2, P  .002).
DISCUSSION
The new finding of this study is the evidence that the
eNOS gene mildly influences the predisposition to AAA
and, in particular, that the G894T polymorphism is mildly
associated with the risk for AAA in patients in whom other
atherosclerotic localizations, such as CAD, CVD, and
PAD, were excluded. Moreover, this study is novel in
evaluating, through the analysis of other two polymor-
phisms, the G894T in the exon 7 and T-786C in the
promoter region, both of which are proposed to be func-
tionally involved in the transcriptional pathway, the possi-
ble influence of the eNOS gene in the pathogenesis of AAA.
NOmodulates vascular disease and maintains endothe-
lial function and antithrombotic intravascular environ-
ment. Its actions are together likely to prevent the devel-
opment of atherosclerotic plaques. There is good evidence
that NOgeneration is depressed in blood vessels affected by
atherosclerosis as well as in blood vessels exposed to ath-
erosclerotic risk factors. In addition to the acquired defects
in NO generation, which can contribute to endothelial
dysfunction and to the development of atherosclerosis,
there is evidence that inherited differences in endothelial
function could also play a role.
eNOS expressed in the endothelial layer is strategically
positioned to affect luminal and abluminal processes. An
experimental study in a murine model2 demonstrated that
the eNOS deficiency is able to change the disease pattern of
atherosclerosis, thus determining PAD, myocardial isch-
emia, and vascular complications, such as aortic dissection
and AAA formation. Moreover, data from eNOS knockout
mice provide evidence that NO is amajor regulator of vessel
reorganization in response to a remodeling stimulus and
suggests that a primary defect in NOS/NO pathway can
promote abnormal remodeling and may facilitate patho-
logic changes in vessel wall morphology.6 Polymorphisms
in the eNOS gene have been related to impaired expression
and functional activity of the enzyme, so modulating the
NO availability.
The present study demonstrated that the eNOSG894T
polymorphism, which has been reported to be associated
with coronary artery disease18 and carotid atherosclero-
sis,19 represents a susceptibility to AAA factor. Moreover,
our findings, by analyzing the role of all three eNOS gene
polymorphisms in AAA patients, provided an extended
evaluation of the genetic influence of the eNOS gene in
modulating atherosclerotic predisposition. A number ofspecific factors can alter the production of NO, thus influ-
encing the progression of atherosclerosis. As conditions
when vascular tissue levels of tetrahydrobiopterin (BH4), a
cofactor for NOS, are deficient or lacking, eNOS becomes
dysfunctional and produces superoxide rather than NO20;
moreover, in animal model of hyperlipidemia, it has been
demonstrated that atherogenesis may be promoted via
increased superoxide generation from dysfunctional
eNOS.21
Actually, the G894T polymorphism might impair the
function of eNOS, thereby accounting for the reduction in
NO availability.7 This might be due to the fact that the
894T rare variant, but not the 894G wild-type allele, is
susceptible to inactivation by cleavage, possibly because of
a tighter turn of the alpha helix,8 thus determining a
reduction in the capacity for NO production.
The study has some limitations: First, because of its
case-control design, the study was able to determine the
predisposition to the disease for genetic polymorphisms;
second, we were not able to perform a Doppler examina-
tion in all the relatives, thus excluding familial AAA only on
the basis of self-reported data, as confirmed by the physi-
cians. Third, the control group consists of truly healthy
subjects with statistically significant differences for tradi-
tional risk factors as compared to AAA patients. A popula-
tion study of patients with AAA compared to subjects
without AAA but with similar prevalence of traditional risk
factor would be the best way to test the potential associa-
tion between genetic polymorphisms and the disease.
Our findings demonstrate that the 894T rare variant
affects the predisposition to AAA; the effect of one gene on
complex diseases, such as AAA,might be difficult to explore
in a population study exposed to environmental confound-
ing factors known to influence the disease. To date, hyper-
tension represents a relevant factor affecting the AAA
pathogenesis; no definitive data on the role of the eNOS
gene in modulating the predisposition to hypertension22,23
are available in literature. Nevertheless, we demonstrated
that the effect of the eNOS gene is relevant independently
from hypertension.
In conclusion, the present study showed that the eNOS
G894T polymorphism is a mild modulator of the predispo-
sition to AAA apart from traditional risk factors, suggesting
a genetically determined influence on the molecular mech-
anisms responsible for this complex disease and a major
direct effect on eNOS activity.
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